Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
MODIA™ - our digital therapy for opioid dependence
- to be used along with pharmaceuticals
- 6 months treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. up to 400 patients
Key News
DECEMBER 22, 2021
Robert Rönn, SVP and Head of R&D: My vision is to develop several new drugs based on amorphOX™
DECEMBER 2, 2021
Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform
NOVEMBER 26, 2021
Orexo provides information about its new proprietary drug delivery platform – amorphOX™
Orexo Social
@OrexoABpubl
20 January 2022
Next week on January 27 we will announce the Q4 Report. The same day we invite to a call where members of Orexo´s m… https://t.co/nNS5qF8Gvj
@OrexoABpubl
18 January 2022
Today we look forward to have Mikaela Odlander, Director & head of Digital Therapeutics EMEAA, joining a panel sess… https://t.co/L5UcDg8h5y
@OrexoABpubl
12 January 2022
We’re hiring! By joining our US SALES FORCE you’ll experience unique opportunities to make a difference to people’s… https://t.co/4qfKI632qF
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
News Flow
Press Releases & News
Invitation to presentation of the Q4 Interim Report, on January 27 at 2 pm CET
Robert Rönn, SVP and Head of R&D: “My vision is to develop several new drugs based on amorphOX™”
Orexo develops a nasal adrenaline medication based on the novel amorphOX platform
Orexo provides information about its new proprietary drug delivery platform – amorphOX™
Financial Snapshot
Group net revenues
580 MSEK
LTM1
Group EBITDA
-112 MSEK
LTM1
US Pharma segment EBIT
301 MSEK
LTM1
Cash position
588 MSEK
Q3 2021
1 Last Twelve Months, Q420-Q321, for more information about financial development Link